Open in Screener

AXSM

Axsome Therapeutics Inc

Aug 29 • 04:00PM ET

121.28

Dollar change -0.47
Percentage change -0.39	%

Healthcare • Biotechnology • USA • NASD

Peers: BIIB ACAD VRTX ALKS NBIX BHVN SAGE PRTA AVDL RARE

| Held by: VTI IWM VB VBK VXF IWO IBB SCHA VTWO IHE

Index	RUT	P/E	-	EPS (ttm)	-5.07	Insider Own	17.75%	Shs Outstand	49.82M	Perf Week	2.34%
Market Cap	6.05B	Forward P/E	107.06	EPS next Y	1.13	Insider Trans	-2.30%	Shs Float	41.08M	Perf Month	19.63%
Enterprise Value	5.97B	PEG	-	EPS next Q	-0.83	Inst Own	75.87%	Short Float	9.06%	Perf Quarter	15.33%
Income	-246.90M	P/S	12.23	EPS this Y	42.10%	Inst Trans	1.26%	Short Ratio	5.83	Perf Half Y	-4.91%
Sales	495.03M	P/B	82.68	EPS next Y	132.67%	ROA	-41.57%	Short Interest	3.72M	Perf YTD	43.34%
Book/sh	1.47	P/C	19.97	EPS next 5Y	-	ROE	-280.68%	52W High	139.13 -12.83%	Perf Year	36.38%
Cash/sh	6.07	P/FCF	-	EPS past 3/5Y	-20.03% -24.44%	ROIC	-113.24%	52W Low	75.56 60.51%	Perf 3Y	83.09%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	89.78%	Volatility	2.79% 3.53%	Perf 5Y	57.45%
Dividend TTM	-	EV/Sales	12.06	EPS Y/Y TTM	22.16%	Oper. Margin	-42.05%	ATR (14)	3.52	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	1.51	Sales Y/Y TTM	69.83%	Profit Margin	-49.88%	RSI (14)	70.77	Recom	1.05
Dividend Gr. 3/5Y	- -	Current Ratio	1.57	EPS Q/Q	41.82%	SMA20	8.46%	Beta	0.54	Target Price	175.67
Payout	-	Debt/Eq	3.06	Sales Q/Q	72.13%	SMA50	12.17%	Rel Volume	0.55	Prev Close	121.75
Employees	683	LT Debt/Eq	1.98	Earnings	Aug 04 BMO	SMA200	13.41%	Avg Volume	638.38K	Price	121.28
IPO	Nov 19, 2015	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.07% 8.71%	Trades		Volume	351,676	Change	-0.39%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-03-25	Resumed	Morgan Stanley	Overweight	$190
Jun-03-25	Initiated	Oppenheimer	Outperform	$185
Apr-07-25	Initiated	Jefferies	Buy	$200
Feb-11-25	Initiated	Deutsche Bank	Buy	$176
Dec-31-24	Reiterated	Mizuho	Outperform	$124 → $122
Sep-03-24	Initiated	Wells Fargo	Overweight	$140
Aug-06-24	Upgrade	BofA Securities	Neutral → Buy	$95 → $106
Jul-22-24	Initiated	Needham	Buy	$130
Apr-29-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$90 → $115
Mar-19-24	Initiated	Robert W. Baird	Outperform	$108
Feb-06-24	Initiated	UBS	Buy	$111
Jan-25-24	Initiated	RBC Capital Mkts	Outperform	$126
Dec-13-23	Initiated	Citigroup	Buy	$125
Aug-08-23	Upgrade	BofA Securities	Underperform → Neutral	$59 → $81
Jan-05-23	Initiated	Piper Sandler	Neutral	$75
Nov-01-22	Initiated	Loop Capital	Buy	$95
Sep-07-22	Resumed	Mizuho	Buy	$49 → $76
Aug-10-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$105 → $34
Jun-10-21	Initiated	Berenberg	Buy	$112
Jan-08-21	Initiated	Jefferies	Buy	$129

Show Previous Ratings

Aug-29-25 12:27PM	Axsome Shares Up 20% in a Month: How Should You Play the Stock? (Zacks)
Aug-27-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-21-25 06:55PM	ReAlta Life Sciences Secures European Orphan Drug Status for Graft-vs-Host Disease Treatment (Exec Edge)
Aug-05-25 11:36AM	AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
03:09AM	Axsome Therapeutics Inc (AXSM) Q2 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
09:30AM	Loading…
Aug-04-25 09:30AM	Here's What Key Metrics Tell Us About Axsome (AXSM) Q2 Earnings (Zacks)
08:10AM	Axsome Therapeutics (AXSM) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
07:12AM	Axsome: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Aug-03-25 02:00PM	Palantir, Advanced Micro, Walt Disney, Pfizer, ZoomInfo, and More Stocks to Watch This Week (Barrons.com)
Jul-30-25 07:30AM	2 Growth Stocks Wall Street Predicts Will Soar 74% to 159% (Barchart)
Jul-29-25 10:00AM	Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-28-25 10:00AM	Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-24-25 05:51AM	2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now (Motley Fool)
Jul-22-25 09:39AM	ALKS Down Despite Positive Top-Line Data From Narcolepsy Study (Zacks) -6.50%
07:30AM	Loading…
Jul-21-25 07:30AM	Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline (GlobeNewswire)
07:00AM	Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today (GlobeNewswire)
Jul-09-25 07:00AM	Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4 (GlobeNewswire)
Jul-07-25 07:00AM	Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21 (GlobeNewswire)
Jul-06-25 04:15AM	Morgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating (Insider Monkey)
Jul-04-25 07:48AM	Here's Why Harmony Biosciences Is an Unconventional Cannabis Investment (Zacks)
03:23AM	Piper Sandler Reaffirms Price Target on Axsome (AXSM) Despite AXS-14 FDA Hurdle (Insider Monkey)
Jun-20-25 07:00AM	Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month (GlobeNewswire)
Jun-18-25 07:00AM	Axsome Therapeutics to Present Data Spanning the SYMBRAVO (meloxicam and rizatriptan) Clinical Program at the 67th Annual Scientific Meeting of the American Headache Society (AHS) (GlobeNewswire)
Jun-16-25 07:00AM	Axsome Therapeutics Proudly Supports Migraine and Headache Awareness Month Alongside the Association of Migraine Disorders (GlobeNewswire)
Jun-11-25 07:57PM	Axsome's AXS-14 Gets Regulatory Setback with RTF, says Morgan Stanley (Insider Monkey)
07:00AM	Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025 (GlobeNewswire)
Jun-10-25 07:00AM	Axsome Therapeutics Announces Availability of SYMBRAVO (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults (GlobeNewswire)
Jun-09-25 07:00AM	Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia (GlobeNewswire)
Jun-05-25 03:19AM	2 Soaring Stocks Wth More Upside Potential (Motley Fool)
11:30AM	Loading…
Jun-04-25 11:30AM	Why Is Axsome (AXSM) Down 1.8% Since Last Earnings Report? (Zacks)
May-29-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-28-25 07:00AM	Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting (GlobeNewswire)
May-27-25 07:00AM	Axsome Therapeutics Settles SUNOSI (solriamfetol) Patent Litigation with Hetero Labs Ltd. (GlobeNewswire)
May-24-25 06:40AM	3 High-Flying Stocks That Could Soar Even More (Motley Fool)
May-14-25 07:30PM	Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis (Motley Fool)
May-13-25 07:00AM	Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone (GlobeNewswire)
May-12-25 07:08AM	Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years (Motley Fool)
May-11-25 11:15AM	3 Monster Stocks in the Making (Motley Fool)
May-06-25 09:39AM	AXSM Q1 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y (Zacks)
03:02AM	Axsome Therapeutics Inc (AXSM) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
12:24AM	Q1 2025 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-05-25 11:44AM	Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript (Seeking Alpha)
09:30AM	Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
08:15AM	Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-01-25 07:00AM	Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month (GlobeNewswire)
Apr-30-25 10:01AM	TG Therapeutics (TGTX) to Report Q1 Results: Wall Street Expects Earnings Growth (Zacks)
Apr-28-25 10:00AM	Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline (Zacks)
Apr-22-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-10-25 09:52AM	Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last? (Zacks) -5.92%
06:18AM	Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy (TipRanks)
Apr-08-25 07:00AM	Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 (GlobeNewswire)
Apr-04-25 07:00AM	Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) -8.37%
Apr-02-25 03:00PM	Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More (Zacks)
11:29AM	AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol (Zacks)
09:33AM	Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680 (Zacks)
Apr-01-25 04:04PM	Axsome Therapeutics Dives Again On Its Second Big Drug Failure In A Week (Investor's Business Daily)
01:23PM	Why Shares of Axsome Therapeutics Slumped Today (Motley Fool)
07:00AM	Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS) (GlobeNewswire)
Mar-26-25 11:51AM	AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint (Zacks)
Mar-25-25 06:47PM	Why Pharma and Biotech Stocks Got Thrashed on Tuesday (Motley Fool) -6.82%
12:53PM	IBD 50's Axsome Therapeutics Dives On Mixed ADHD Results. Why Analysts Aren't Worried. (Investor's Business Daily)
07:00AM	Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint (GlobeNewswire)
Mar-21-25 11:36AM	Axsome: The Alzheimer's Agitation Program For AXS-05 (SeekingAlpha)
Mar-20-25 12:00PM	Lazard US Equity Concentrated Portfolio Q4 2024 Commentary (SeekingAlpha)
11:30AM	Axsome (AXSM) Down 0.8% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-19-25 12:14PM	HRMY Down 10.8% in Six Months: How Should You Play the Stock? (Zacks)
Mar-14-25 10:32AM	Is Axsome Therapeutics, Inc. (AXSM) the Best Performing Growth Stock in 2025? (Insider Monkey)
Mar-05-25 07:00AM	Axsome Therapeutics Settles Sunosi (solriamfetol) Patent Litigation with Hikma Pharmaceuticals USA (GlobeNewswire)
Mar-03-25 07:00AM	Axsome Therapeutics Announces FDA Pre-NDA Meeting Minutes for AXS-05 in Alzheimer's Disease Agitation Supporting NDA Submission (GlobeNewswire)
Mar-01-25 05:04PM	Why Axsome Therapeutics, Inc. (AXSM) is Skyrocketing So Far in 2025 (Insider Monkey)
Feb-26-25 07:00AM	Axsome Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-24-25 01:34PM	Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs (Benzinga) -5.10%
07:00AM	Axsome Therapeutics Announces SYMBRAVO (meloxicam and rizatriptan) Achieves Primary Endpoint in the EMERGE Phase 3 Trial in Migraine Patients Experiencing Inadequate Response to Oral CGRP Inhibitors (GlobeNewswire)
Feb-23-25 03:09PM	Why Axsome Therapeutics, Inc. (AXSM) is the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-21-25 04:58PM	These Biotech Stocks Aren't Profitable But Still Make Elite IBD 50 (Investor's Business Daily) +6.70% -5.10%
Feb-19-25 02:48PM	Axsome Therapeutics, Inc. (AXSM): the Best Performing Healthcare Stock So Far in 2025 (Insider Monkey)
02:03AM	Axsome Therapeutics Inc (AXSM) Q4 2024 Earnings Call Highlights: Robust Revenue Growth Amid ... (GuruFocus.com)
01:06AM	Q4 2024 Axsome Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-18-25 11:15AM	Axsome Therapeutics (AXSM) Q4 2024 Earnings Call Transcript (Motley Fool)
07:00AM	Axsome Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-16-25 09:45AM	This Stock Is Already Up by 55% in 2025: Is It Too Late to Buy? (Motley Fool)
Feb-11-25 02:42PM	Why Axsome Therapeutics (AXSM) Is Advancing Today (Insider Monkey)
11:39AM	Why Axsome Therapeutics Stock Is Soaring Today (Motley Fool)
03:33AM	Axsome (AXSM) Surges 20.2%: Is This an Indication of Further Gains? (Zacks)
Feb-10-25 02:45PM	Why Axsome Therapeutics Stock Is Skyrocketing Today (Motley Fool) +20.16%
12:33PM	Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' (Benzinga)
07:00AM	Axsome Therapeutics Announces Settlement Agreement Resolving AUVELITY (dextromethorphan HBr bupropion HCl) Patent Litigation (GlobeNewswire)
Jan-31-25 07:00AM	Axsome Therapeutics Hosts SYMBRAVO FDA Approval Virtual Investor Event with Expert Thought Leader (GlobeNewswire)
Jan-30-25 03:45PM	Axsome Therapeutics Announces FDA Approval of SYMBRAVO (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults (GlobeNewswire)
Jan-22-25 07:00AM	Axsome Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 18 (GlobeNewswire) +6.33%
Jan-13-25 04:15PM	BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. (Investor's Business Daily) +11.52% -5.23%
07:00AM	Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2024 Net Revenue (GlobeNewswire)
Dec-31-24 08:15AM	Axsome Reveals Data From Alzheimer's Studies, Analyst Sees Hope Despite Mixed Trial Results (Benzinga)
Dec-30-24 05:07PM	Axsome Flashes A Bearish Signal On Mixed Results In Alzheimer's Agitation (Investor's Business Daily)
07:00AM	Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer's Disease Agitation (GlobeNewswire)
Dec-12-24 11:30AM	Why Is Axsome (AXSM) Down 0.1% Since Last Earnings Report? (Zacks)
Nov-27-24 01:23PM	Axsome Therapeutics' AXS-12 Data For Sleeping Disorder Boosts Confidence In Approval And Market Potential, Analyst Says (Benzinga)
Nov-26-24 07:00AM	Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in ENCORE Long-Term Phase 3 Trial in Narcolepsy (GlobeNewswire)

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
JEFFS ROGER	Director	Aug 27 '25	Sale	122.30	20,000	2,446,000	110,974	Aug 29 07:08 PM
JEFFS ROGER	Director	Aug 28 '25	Sale	121.60	20,000	2,432,000	90,974	Aug 29 07:08 PM
JEFFS ROGER	Director	Aug 29 '25	Sale	121.27	20,000	2,425,400	70,974	Aug 29 07:08 PM
JEFFS ROGER	Director	Aug 29 '25	Proposed Sale	121.27	20,000	2,425,335		Aug 29 04:02 PM
JEFFS ROGER	Director	Aug 28 '25	Proposed Sale	121.60	20,000	2,432,004		Aug 28 04:04 PM
JEFFS ROGER	Director	Aug 27 '25	Proposed Sale	122.30	20,000	2,446,052		Aug 27 04:12 PM
JEFFS ROGER	Director	Aug 26 '25	Sale	120.03	20,000	2,400,600	130,974	Aug 26 07:00 PM
JEFFS ROGER	Director	Aug 22 '25	Sale	120.08	16,694	2,004,616	150,974	Aug 26 07:00 PM
JEFFS ROGER	Director	Aug 26 '25	Proposed Sale	120.03	20,000	2,400,658		Aug 26 04:08 PM
JEFFS ROGER	Director	Aug 22 '25	Proposed Sale	120.08	16,694	2,004,598		Aug 22 04:28 PM
Murdock Hunter R.	General Counsel	Jun 20 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 23 07:42 PM
Murdock Hunter R.	General Counsel	Jun 23 '25	Option Exercise	29.91	6,014	179,879	6,014	Jun 23 07:42 PM
Murdock Hunter R.	General Counsel	Jun 20 '25	Sale	102.47	7,500	768,525	0	Jun 23 07:42 PM
Murdock Hunter R.	General Counsel	Jun 23 '25	Sale	100.12	6,014	602,122	0	Jun 23 07:42 PM
Murdock Hunter R.	Officer	Jun 23 '25	Proposed Sale	100.12	6,014	602,101		Jun 23 04:01 PM
Murdock Hunter R.	Officer	Jun 20 '25	Proposed Sale	102.47	7,500	768,503		Jun 20 04:08 PM
Murdock Hunter R.	General Counsel	Jun 18 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 16 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 17 '25	Option Exercise	29.91	7,500	224,325	7,500	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 16 '25	Sale	102.42	7,500	768,150	0	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 18 '25	Sale	100.90	7,500	756,750	0	Jun 18 09:16 PM
Murdock Hunter R.	General Counsel	Jun 17 '25	Sale	100.26	7,500	751,950	0	Jun 18 09:16 PM
Murdock Hunter R.	Officer	Jun 18 '25	Proposed Sale	100.90	7,500	756,729		Jun 18 04:42 PM
Murdock Hunter R.	Officer	Jun 17 '25	Proposed Sale	100.26	7,500	751,975		Jun 17 04:01 PM
Murdock Hunter R.	Officer	Jun 16 '25	Proposed Sale	102.42	7,500	768,154		Jun 16 04:17 PM
Jacobson Mark L.	Chief Operating Officer	Jun 09 '25	Option Exercise	8.02	25,000	200,500	30,783	Jun 10 07:00 PM
Jacobson Mark L.	Chief Operating Officer	Jun 09 '25	Sale	110.44	25,000	2,761,000	5,783	Jun 10 07:00 PM
Jacobson Mark L.	Officer	Jun 09 '25	Proposed Sale	110.44	25,000	2,760,894		Jun 09 04:07 PM
Coleman Mark	Director	May 27 '25	Sale	105.47	3,750	395,512	50,387	May 29 07:00 PM
Coleman Mark	Director	May 28 '25	Sale	103.43	3,750	387,862	46,637	May 29 07:00 PM
Jacobson Mark L.	Chief Operating Officer	May 27 '25	Option Exercise	6.47	20,673	133,754	26,456	May 28 09:52 PM
Jacobson Mark L.	Chief Operating Officer	May 28 '25	Option Exercise	6.47	20,000	129,400	25,783	May 28 09:52 PM
Jacobson Mark L.	Chief Operating Officer	May 27 '25	Sale	104.66	20,673	2,163,636	5,783	May 28 09:52 PM
Jacobson Mark L.	Chief Operating Officer	May 28 '25	Sale	103.45	20,000	2,069,000	5,783	May 28 09:52 PM
Coleman Mark	Director	May 28 '25	Proposed Sale	103.43	3,750	387,858		May 28 05:04 PM
Jacobson Mark L.	Officer	May 28 '25	Proposed Sale	103.45	20,000	2,068,932		May 28 05:03 PM
Jacobson Mark L.	Officer	May 27 '25	Proposed Sale	0.00	20,673	1		May 27 04:46 PM
Coleman Mark	Director	May 27 '25	Proposed Sale	105.47	3,750	395,501		May 27 04:45 PM
Coleman Mark	Director	May 20 '25	Sale	107.49	3,000	322,473	54,137	May 20 09:46 PM
Coleman Mark	Director	May 20 '25	Proposed Sale	107.49	3,000	322,473		May 20 05:54 PM
Pizzie Nick	Chief Financial Officer	Feb 13 '25	Option Exercise	3.50	12,000	42,000	54,187	Feb 14 09:20 PM
Pizzie Nick	Chief Financial Officer	Feb 14 '25	Option Exercise	3.50	3,000	10,500	45,187	Feb 14 09:20 PM
Pizzie Nick	Chief Financial Officer	Feb 13 '25	Sale	129.86	12,000	1,558,320	42,187	Feb 14 09:20 PM
Pizzie Nick	Chief Financial Officer	Feb 14 '25	Sale	131.07	3,000	393,210	42,187	Feb 14 09:20 PM
Pizzie Nick	Officer	Feb 14 '25	Proposed Sale	131.07	3,000	393,202		Feb 14 04:09 PM
Pizzie Nick	Officer	Feb 13 '25	Proposed Sale	129.86	12,000	1,558,312		Feb 13 04:02 PM
Coleman Mark	Director	Jan 03 '25	Option Exercise	9.00	9,127	82,143	57,137	Jan 06 04:06 PM
Coleman Mark	Director	Nov 19 '24	Option Exercise	5.94	33,410	198,455	48,010	Nov 20 04:30 PM
Saad Mark E	Director	Sep 11 '24	Option Exercise	3.67	11,016	40,429	21,018	Sep 11 07:00 PM
Saad Mark E	Director	Sep 11 '24	Sale	91.31	11,016	1,005,871	10,002	Sep 11 07:00 PM
Saad Mark E	Director	Sep 11 '24	Proposed Sale	91.31	11,016	1,005,843		Sep 11 04:32 PM

Open in Screener

LQDA

Liquidia Corp

Aug 29 • 04:00PM ET

27.68

Dollar change +0.22
Percentage change 0.80	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX ALNY SRPT NBIX ARWR IONS RGEN MDGL XNCR

| Held by: IWM VTI IWO VXF KOMP SCHA VTWO XPH IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-1.69	Insider Own	18.58%	Shs Outstand	85.86M	Perf Week	3.13%
Market Cap	2.38B	Forward P/E	43.50	EPS next Y	0.64	Insider Trans	-1.56%	Shs Float	70.10M	Perf Month	48.10%
Enterprise Value	2.37B	PEG	-	EPS next Q	-0.41	Inst Own	67.20%	Short Float	26.23%	Perf Quarter	85.52%
Income	-141.47M	P/S	123.34	EPS this Y	3.15%	Inst Trans	11.92%	Short Ratio	6.64	Perf Half Y	78.70%
Sales	19.32M	P/B	156.47	EPS next Y	139.57%	ROA	-65.08%	Short Interest	18.39M	Perf YTD	135.37%
Book/sh	0.18	P/C	13.74	EPS next 5Y	-	ROE	-363.16%	52W High	28.82 -3.96%	Perf Year	186.84%
Cash/sh	2.01	P/FCF	-	EPS past 3/5Y	-33.51% 8.44%	ROIC	-82.72%	52W Low	8.75 216.34%	Perf 3Y	272.04%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-3.36% 11.64%	Gross Margin	63.81%	Volatility	4.79% 6.54%	Perf 5Y	455.82%
Dividend TTM	-	EV/Sales	122.45	EPS Y/Y TTM	-7.22%	Oper. Margin	-715.38%	ATR (14)	1.32	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.41	Sales Y/Y TTM	30.20%	Profit Margin	-732.17%	RSI (14)	71.94	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	2.49	EPS Q/Q	-32.88%	SMA20	11.73%	Beta	0.25	Target Price	36.67
Payout	-	Debt/Eq	10.29	Sales Q/Q	141.51%	SMA50	46.36%	Rel Volume	0.79	Prev Close	27.46
Employees	157	LT Debt/Eq	10.26	Earnings	Aug 12 BMO	SMA200	82.72%	Avg Volume	2.77M	Price	27.68
IPO	Jul 26, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-13.56% 118.43%	Trades		Volume	2,173,314	Change	0.80%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-15-25	Resumed	Jefferies	Buy	$43
May-19-25	Downgrade	Oppenheimer	Perform → Underperform	$13
Dec-20-24	Initiated	Wells Fargo	Overweight	$20
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-19-24	Upgrade	Raymond James	Outperform → Strong Buy
Aug-16-24	Initiated	Raymond James	Outperform	$27
Jun-25-24	Initiated	Oppenheimer	Perform
Jan-05-24	Reiterated	Needham	Buy	$18 → $28
Sep-19-22	Resumed	Wedbush	Underperform	$3
Sep-01-22	Downgrade	Wedbush	Neutral → Underperform	$3
Jul-22-22	Initiated	Ladenburg Thalmann	Buy	$15
May-31-22	Initiated	BTIG Research	Buy	$14
May-26-22	Initiated	BofA Securities	Buy	$12
Dec-04-20	Initiated	H.C. Wainwright	Buy	$6
Nov-20-20	Downgrade	Wedbush	Outperform → Neutral	$20 → $4
Nov-08-18	Resumed	Jefferies	Buy
Sep-05-18	Initiated	Wedbush	Outperform	$26
Aug-20-18	Initiated	Needham	Buy	$30
Aug-20-18	Initiated	Jefferies	Buy	$22

Show Previous Ratings

Aug-27-25 08:30AM	Liquidia Corporation to Present at the 2025 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-18-25 11:40PM	Court Victory and Fresh Funding Propel Growth at Liquidia Corporation (Insider Monkey) +6.82%
Aug-13-25 12:54PM	Liquidia (LQDA) Climbs 13.68% as Yutrepia Prescriptions Surge (Insider Monkey)
03:08AM	Liquidia Corp (LQDA) Q2 2025 Earnings Call Highlights: Strong YUTREPIA Launch and Financial Position (GuruFocus.com)
Aug-12-25 04:06PM	Liquidia Shoots Higher As Yutrepia Launch Kicks Off Amid United Patent Battle (Investor's Business Daily) +13.68%
03:00PM	Loading…
03:00PM	Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
10:00AM	Liquidia Shoots Higher, But At-Risk Launch Could Come Back To Haunt It (Investor's Business Daily)
06:30AM	Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-11-25 09:22AM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q2 2025 Result (GuruFocus.com)
Aug-05-25 08:30AM	Liquidia Corporation to Report Second Quarter 2025 Financial Results on August 12, 2025 (GlobeNewswire)
Jul-31-25 09:15AM	Vericel Corporation (VCEL) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
Jul-24-25 08:00AM	Insmed Is Trading At A 25-Year High. Will Its 'Skeleton Key' Work? (Investor's Business Daily) +5.75%
Jul-15-25 01:08PM	Liquidia Stock Gets Relative Strength Rating Lift (Investor's Business Daily)
08:59AM	Liquidia Receives $50M from HCRx, Accelerates YUTREPIA's Commercial Launch Following Favorable Court Ruling (Insider Monkey)
Jun-23-25 04:34PM	Liquidia Receives $50 Million from Healthcare Royalty (HCRx) Following First Commercial Sale of YUTREPIA (GlobeNewswire)
11:04AM	Loading…
Jun-11-25 11:04AM	Insmed Stock Jumps 29% on Encouraging PAH Study Results (Zacks) -5.67%
Jun-10-25 04:07PM	Insmed Catapults Into Breakout Territory On A 'Home Run' For Its Rival To United, Liquidia (Investor's Business Daily) -16.87%
Jun-02-25 06:30AM	Liquidia Schedules First Commercial Shipment of YUTREPIA (treprostinil) Inhalation Powder for Patients with PAH and PH-ILD (GlobeNewswire) +13.07%
May-28-25 08:00AM	Liquidia Corporation to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire) -9.13%
May-24-25 10:47AM	FDA Approves Liquidia Corporation (LQDA)'s YUTREPIA Amid Patent Dispute (Insider Monkey)
May-23-25 02:28PM	U.S. FDA Approves Liquidia's YUTREPIA (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) (GlobeNewswire)
May-12-25 06:00AM	Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics (GlobeNewswire)
May-09-25 03:21AM	Liquidia Corp (LQDA) Q1 2025 Earnings Call Highlights: Strategic Advances and Legal Wins Propel ... (GuruFocus.com)
May-08-25 11:06AM	Buckley Capital's Views on Liquidia Corp. (LQDA) (Insider Monkey)
07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-25 06:35PM	Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
11:16AM	Liquidia Q1 2025 Earnings Preview (Seeking Alpha)
10:15AM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q1 2025 Result (GuruFocus.com)
08:00AM	Loading…
May-06-25 08:00AM	Liquidia Corporation to Present at BofA Securities 2025 Health Care Conference (GlobeNewswire)
May-05-25 04:06PM	Liquidia Corporation: A Strong Buy On High Likelihood Of FDA Approval This Month (Seeking Alpha)
09:50AM	Liquidia Technologies (LQDA) Surges 13.2%: Is This an Indication of Further Gains? (Zacks)
May-02-25 05:28PM	District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia (GlobeNewswire) +13.23%
May-01-25 08:00AM	Liquidia Corporation to Report First Quarter 2025 Financial Results on May 8, 2025 (GlobeNewswire)
Apr-30-25 09:30AM	Arquitos Capital's Largest Holdings For Q1 2025 (Seeking Alpha)
Apr-29-25 07:40AM	Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates (Zacks) -5.06%
05:16AM	Urogen Pharma (URGN) Moves 14.1% Higher: Will This Strength Last? (Zacks)
Apr-25-25 06:30AM	Arquitos Capital Management Q1 2025 Investor Letter (Seeking Alpha)
Apr-07-25 06:38AM	Liquidia: United Therapeutics Has The Last Laugh (Seeking Alpha)
Apr-01-25 10:33AM	UPDATE Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
08:00AM	Liquidia Corporation to Present at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-28-25 09:30AM	Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA (treprostinil) Inhalation Powder (GlobeNewswire)
Mar-27-25 08:00AM	Liquidia Announces Poster Presentations at the American Thoracic Society (ATS) 2025 International Conference (GlobeNewswire)
Mar-21-25 06:23PM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q4 2024 Result (GuruFocus.com)
Mar-20-25 01:01AM	Q4 2024 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-19-25 11:56AM	Liquidia Corporation (LQDA) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:45AM	Liquidia Technologies, Inc. (LQDA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-18-25 08:00AM	Liquidia Corporation Strengthens Financial Position by Amending HealthCare Royalty Agreement to Incrementally Add Up to $100 Million (GlobeNewswire)
Mar-12-25 08:00AM	Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025 (GlobeNewswire)
Feb-24-25 07:00AM	Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors (GlobeNewswire)
Jan-22-25 09:12AM	Liquidia Technologies (LQDA) Moves 5.7% Higher: Will This Strength Last? (Zacks)
Jan-08-25 08:00AM	Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-27-24 07:11PM	Jim Cramer's Hidden Gem: Why Liquidia Corporation (LQDA) Is the Undervalued Stock You Need to Know (Insider Monkey)
Dec-12-24 10:00AM	Heres Arquitos Capital Managements Updates on Liquidia (LQDA) (Insider Monkey)
09:55AM	Does Liquidia Technologies (LQDA) Have the Potential to Rally 132.54% as Wall Street Analysts Expect? (Zacks)
Nov-26-24 09:55AM	Wall Street Analysts See a 126.13% Upside in Liquidia Technologies (LQDA): Can the Stock Really Move This High? (Zacks)
Nov-14-24 02:09AM	Liquidia Corp (LQDA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Regulatory ... (GuruFocus.com)
Nov-13-24 07:40AM	Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-12-24 08:00AM	Liquidia to Present at the Stifel 2024 Healthcare Conference (GlobeNewswire)
Nov-08-24 07:04AM	Earnings To Watch: Liquidia Corp (LQDA) Reports Q3 2024 Result (GuruFocus.com)
Nov-06-24 08:00AM	Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 13, 2024 (GlobeNewswire)
Nov-04-24 08:00AM	Liquidia Corporation to Report Third Quarter 2024 Financial Results on November 11, 2024 (GlobeNewswire)
Oct-29-24 10:01AM	Liquidia Technologies, Inc. (LQDA) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-09-24 05:12PM	Liquidia Corp (LQDA) Q2 2024 Earnings Call Highlights: Navigating Challenges and Opportunities ... (GuruFocus.com)
Oct-08-24 09:34AM	Liquidia Technologies (LQDA) Surges 11.2%: Is This an Indication of Further Gains? (Zacks)
Oct-07-24 10:00AM	United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics' Patent (GlobeNewswire) +11.17%
Oct-02-24 06:00AM	Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606) (GlobeNewswire)
Sep-30-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Liquidia, Napco, and Franklin and Encourages Investors to Contact the Firm (GlobeNewswire)
08:00AM	Liquidia Announces Poster Presentation and Medical Theater at the CHEST 2024 Annual Meeting (GlobeNewswire)
Sep-16-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Paragon 28, Centuri, Liquidia, and Elastic and Encourages Investors to Contact the Firm (GlobeNewswire)
09:41AM	Court Finds United Therapeutics' Interference with Launch of Generic Treprostinil Injection Caused Losses of More Than $137 Million (GlobeNewswire)
Sep-12-24 07:02PM	Caligan Partners LP Bolsters Portfolio with Significant Stake in Liquidia Corp (GuruFocus.com)
07:00AM	Liquidia Technologies (LQDA) Soars 14.1%: Is Further Upside Left in the Stock? (Zacks)
Sep-11-24 08:26AM	Liquidia Corporation Announces Raise of $67.5 Million from New Common Stock Financings and $32.5 Million Advance from HealthCare Royalty Under Current Financing Agreement (GlobeNewswire) +14.10%
Aug-28-24 08:00AM	Liquidia to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-26-24 02:19PM	Jim Cramer Says Liquidia Corporation (LQDA) Has Been Going Down, Down, Down (Insider Monkey)
Aug-22-24 06:00AM	Liquidia Files Litigation to Challenge Regulatory Exclusivity Blocking Access to YUTREPIA (treprostinil) inhalation powder for Patients Suffering with PAH and PH-ILD (GlobeNewswire)
Aug-20-24 10:27AM	Liquidia (LQDA) Down on FDA Delaying Full Approval for Yutrepia (Zacks)
06:33AM	Liquidias YUTREPIA inhalation powder gains tentative FDA approval (Pharmaceutical Technology)
Aug-19-24 04:01PM	Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 31% (Investor's Business Daily) -30.62%
11:11AM	Midday movers: B. Riley, HP Inc fall; AMD rises (Investing.com)
06:00AM	U.S. FDA Grants Tentative Approval of YUTREPIA (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) (GlobeNewswire)
Aug-16-24 06:30AM	Liquidia Announces Poster Presentations at the PHA 2024 International PH Conference and Scientific Sessions (GlobeNewswire)
Aug-09-24 07:45AM	Why Is Liquidia Corporation (LQDA) The Best Among Caligan Partners Top Holdings? (Insider Monkey)
Aug-07-24 07:40AM	Liquidia Technologies, Inc. (LQDA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
06:30AM	Liquidia Corporation Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-31-24 08:00AM	Liquidia Corporation to Report Second Quarter 2024 Financial Results on August 7, 2024 (GlobeNewswire)
Jun-18-24 08:42AM	Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH) (GlobeNewswire) -6.08%
Jun-03-24 04:33PM	Liquidia Stock Surges After Winning Patent Battle Vs. United Therapeutics (Investor's Business Daily) +12.67%
07:00AM	District Court Issues Favorable Ruling and Denies United Therapeutics' Request to Block YUTREPIA Launch (GlobeNewswire)
May-29-24 08:00AM	Liquidia Corporation to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-24 03:03AM	Liquidia Corp (LQDA) Q1 2024 Earnings Call Transcript Highlights: A Detailed Review of ... (GuruFocus.com)
02:05AM	Q1 2024 Liquidia Corp Earnings Call (Thomson Reuters StreetEvents)
May-14-24 09:35AM	Down -11.26% in 4 Weeks, Here's Why You Should You Buy the Dip in Liquidia Technologies (LQDA) (Zacks)
08:53AM	LQDA Stock Earnings: Liquidia Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
May-13-24 05:43PM	Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-10-24 08:00AM	Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD (GlobeNewswire)

Liquidia Corp. operates as a holding company which engages through its subsidiary in developing and commercializing biopharmaceutical products and novel products development used in PRINT technology to transform the lives of patients. The company was founded in June 2004 and is headquartered in Morrisville, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Manning Paul B	Director	Aug 29 '25	Proposed Sale	27.60	947,328	26,146,253		Aug 29 04:18 PM
RAJEEV SAGGAR	Officer	Aug 28 '25	Proposed Sale	28.00	20,000	560,000		Aug 28 04:23 PM
JASON ADAIR	Officer	Aug 28 '25	Proposed Sale	28.00	26,057	729,596		Aug 28 04:19 PM
Manning Paul B	Director	Aug 28 '25	Proposed Sale	27.94	154,337	4,312,469		Aug 28 04:11 PM
Horobin Joanna	Director	Aug 19 '25	Sale	27.17	5,000	135,850	33,755	Aug 21 04:30 PM
Horobin Joanna	Director	Aug 19 '25	Proposed Sale	27.17	5,000	135,850		Aug 19 07:28 PM
Kaseta Michael	CFO and COO	Aug 15 '25	Sale	26.18	20,000	523,674	356,412	Aug 19 04:30 PM
Kaseta Michael	CFO and COO	Aug 05 '25	Sale	20.00	30,000	600,132	376,412	Aug 07 04:30 PM
MICHAEL KASETA	Officer	Aug 05 '25	Proposed Sale	19.48	50,000	974,000		Aug 05 05:02 PM
Adair Jason	Chief Business Officer	Jul 28 '25	Sale	19.54	454	8,871	193,180	Jul 30 04:31 PM
Boyle Dana	Chief Accounting Officer	Jul 28 '25	Sale	19.54	1,063	20,771	186,105	Jul 30 04:30 PM
Saggar Rajeev	Chief Medical Officer	Jul 21 '25	Sale	14.54	2,526	36,728	268,887	Jul 23 04:30 PM
Schundler Russell	General Counsel	Jul 14 '25	Sale	14.28	7,836	111,898	577,977	Jul 15 04:36 PM
Saggar Rajeev	Chief Medical Officer	Jul 14 '25	Sale	14.28	5,327	76,070	271,413	Jul 15 04:36 PM
Moomaw Scott	Chief Commercial Officer	Jul 14 '25	Sale	14.28	4,797	68,501	223,231	Jul 15 04:35 PM
Krepp Sarah	Chief Human Resource Officer	Jul 14 '25	Sale	14.28	2,673	38,170	142,499	Jul 15 04:35 PM
Kaseta Michael	CFO and COO	Jul 14 '25	Sale	14.28	11,580	165,362	406,412	Jul 15 04:34 PM
JEFFS ROGER	Chief Executive Officer	Jul 14 '25	Sale	14.28	20,252	289,199	1,038,560	Jul 15 04:33 PM
JEFFS ROGER	Chief Executive Officer	Jul 14 '25	Sale	14.28	20,252	289,199	1,038,560	Jul 15 04:33 PM
Boyle Dana	Chief Accounting Officer	Jul 14 '25	Sale	14.28	1,193	17,036	187,168	Jul 15 04:30 PM
Adair Jason	Chief Business Officer	Jul 14 '25	Sale	14.28	2,576	36,785	193,634	Jul 15 04:30 PM
Schundler Russell	General Counsel	Jun 04 '25	Sale	16.97	8,460	143,566	582,054	Jun 05 04:20 PM
Moomaw Scott	Chief Commercial Officer	Jun 04 '25	Sale	16.97	6,656	112,952	224,921	Jun 05 04:20 PM
Saggar Rajeev	Chief Medical Officer	Jun 04 '25	Sale	16.97	7,597	128,921	273,209	Jun 05 04:19 PM
JEFFS ROGER	Chief Executive Officer	Jun 04 '25	Sale	16.97	30,610	519,452	1,044,979	Jun 05 04:18 PM
Kaseta Michael	CFO and COO	Jun 04 '25	Sale	16.97	14,777	250,766	412,164	Jun 05 04:18 PM
Adair Jason	Chief Business Officer	Jun 04 '25	Sale	16.97	3,597	61,041	193,735	Jun 05 04:15 PM
Schundler Russell	General Counsel	Jun 02 '25	Sale	16.74	923	15,451	571,722	Jun 03 04:49 PM
Moomaw Scott	Chief Commercial Officer	Jun 02 '25	Sale	16.74	581	9,726	216,038	Jun 03 04:47 PM
Kaseta Michael	CFO and COO	Jun 02 '25	Sale	16.74	859	14,380	397,800	Jun 03 04:45 PM
Adair Jason	Chief Business Officer	Jun 02 '25	Sale	16.74	451	7,550	184,961	Jun 03 04:44 PM
Adair Jason	Chief Business Officer	Apr 28 '25	Sale	14.24	455	6,479	183,849	Apr 30 04:15 PM
Saggar Rajeev	Chief Medical Officer	Apr 21 '25	Sale	13.67	2,450	33,492	263,152	Apr 23 04:15 PM
Schundler Russell	General Counsel	Apr 14 '25	Sale	13.57	5,964	80,931	570,301	Apr 16 05:06 PM
JEFFS ROGER	Chief Executive Officer	Apr 14 '25	Sale	13.57	14,130	191,744	1,006,420	Apr 16 05:05 PM
Moomaw Scott	Chief Commercial Officer	Apr 15 '25	Sale	13.57	3,406	46,219	214,744	Apr 16 05:04 PM
Kaseta Michael	CFO and COO	Apr 14 '25	Sale	13.57	8,283	112,400	396,315	Apr 16 05:03 PM
Saggar Rajeev	Chief Medical Officer	Apr 14 '25	Sale	13.57	3,714	50,399	265,602	Apr 16 05:02 PM
Adair Jason	Chief Business Officer	Apr 14 '25	Sale	13.57	1,856	25,186	184,304	Apr 15 09:12 PM
Schundler Russell	General Counsel	Mar 03 '25	Sale	15.45	930	14,368	576,265	Mar 04 04:32 PM
Moomaw Scott	Chief Commercial Officer	Mar 03 '25	Sale	15.45	592	9,146	218,150	Mar 04 04:31 PM
Kaseta Michael	CFO and COO	Mar 03 '25	Sale	15.45	874	13,503	404,598	Mar 04 04:31 PM
Adair Jason	Chief Business Officer	Mar 03 '25	Sale	15.45	451	6,968	182,254	Mar 04 04:30 PM
Adair Jason	Chief Business Officer	Jan 27 '25	Sale	14.20	445	6,319	179,770	Jan 29 04:40 PM
Saggar Rajeev	Chief Medical Officer	Jan 21 '25	Sale	13.00	2,445	31,785	267,943	Jan 23 05:00 PM
Schundler Russell	General Counsel	Jan 14 '25	Sale	11.78	16,393	193,110	573,478	Jan 14 04:39 PM
Saggar Rajeev	Chief Medical Officer	Jan 14 '25	Sale	11.78	6,249	73,613	270,388	Jan 14 04:39 PM
Moomaw Scott	Chief Commercial Officer	Jan 14 '25	Sale	11.78	8,362	98,504	215,494	Jan 14 04:38 PM
Kaseta Michael	CFO and COO	Jan 14 '25	Sale	11.78	23,370	275,299	401,755	Jan 14 04:37 PM
Adair Jason	Chief Business Officer	Jan 14 '25	Sale	11.78	4,809	56,650	180,215	Jan 14 04:36 PM
JEFFS ROGER	Chief Executive Officer	Jan 14 '25	Sale	11.78	22,343	263,201	1,019,177	Jan 14 04:35 PM
Moomaw Scott	Chief Commercial Officer	Dec 02 '24	Sale	11.51	546	6,284	154,127	Dec 03 09:45 PM
Kaseta Michael	CFO and COO	Dec 02 '24	Sale	11.51	1,091	12,557	312,328	Dec 03 09:44 PM
Schundler Russell	General Counsel	Dec 02 '24	Sale	11.51	1,063	12,235	487,328	Dec 03 09:43 PM
Adair Jason	Chief Business Officer	Dec 02 '24	Sale	11.51	455	5,237	119,223	Dec 03 09:43 PM
Saggar Rajeev	Chief Medical Officer	Oct 18 '24	Sale	11.19	2,526	28,266	204,857	Oct 22 04:15 PM
Schundler Russell	General Counsel	Oct 14 '24	Sale	11.11	2,576	28,613	486,048	Oct 15 08:12 PM
Saggar Rajeev	Chief Medical Officer	Oct 14 '24	Sale	11.11	2,260	25,103	207,383	Oct 15 08:11 PM
Moomaw Scott	Chief Commercial Officer	Oct 14 '24	Sale	11.11	1,527	16,961	152,798	Oct 15 08:10 PM
Kaseta Michael	CFO and COO	Oct 14 '24	Sale	11.11	3,892	43,231	311,076	Oct 15 08:08 PM
JEFFS ROGER	Chief Executive Officer	Oct 14 '24	Sale	11.11	8,053	89,450	812,193	Oct 15 08:06 PM
Adair Jason	Chief Business Officer	Oct 14 '24	Sale	11.11	1,146	12,729	118,574	Oct 15 08:06 PM
Manning Paul B	Director	Sep 12 '24	Buy	8.90	337,078	2,999,994	816,311	Sep 16 04:05 PM
Adair Jason	Chief Business Officer	Sep 03 '24	Sale	9.50	455	4,322	115,814	Sep 04 04:51 PM
Schundler Russell	General Counsel	Sep 03 '24	Sale	9.50	710	6,745	488,624	Sep 04 04:44 PM
Moomaw Scott	Chief Commercial Officer	Sep 03 '24	Sale	9.50	546	5,187	154,325	Sep 04 04:44 PM
Kaseta Michael	CFO and COO	Sep 03 '24	Sale	9.50	1,079	10,250	314,968	Sep 04 04:40 PM

AXSM

Axsome Therapeutics Inc

LQDA

Liquidia Corp

Upgrade your FINVIZ experience